The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
Open accessAbstract
The traditional classification of lung cancer into small cell lung cancer and non‐small cell lung cancer (NSCLC) has been transformed with the increased understanding of the molecular alterations and genomic biomarkers that drive the development of lung cancer. Increased activation of the phosphatidylinositol 3‐kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway leads to numerous hallmarks of cancer and this pathway represents an attractive target for novel anticancer therapies. In NSCLC, the PI3K/Akt/mTOR pathway has been heavily implicated in both tumorigenesis and the progression of disease. A number of specific inhibitors of PI3K, Akt and mTOR are currently under development and in various stages of preclinical investigation and in early phase clinical trials for NSCLC. Early evidence has yielded disappointing results. Clinical trials, however, have been performed on predominantly molecularly unselected populations, and patient enrichment strategies using high‐precision predictive biomarkers in future trials will increase the likelihood of success. A greater understanding of the underlying molecular biology including epigenetic alterations is also crucial to allow for the detection of appropriate biomarkers and guide combination approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., & Roberts, T. M. (1985) · Nature · doi:10.1038/315239a0 · Cited by 810
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi, Y., Watanabe, Y., Miwa, C., Suzuki, S., & Koyama, S. (2011) · PubMed · Cited by 750
PTEN: a tumour suppressor that functions as a phospholipid phosphatase
Maehama, T. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01519-6 · Cited by 590
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
(1997) · PubMed · Cited by 512
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5084 · Cited by 429
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406
The life of a cell: apoptosis regulation by the PI3K/PKB pathway
Duronio, V. (2008) · Biochemical Journal · doi:10.1042/bj20081056 · Cited by 390
Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., & Cantley, L. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98375-4 · Cited by 388
Classes of phosphoinositide 3-kinases at a glance
Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 379
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Balsara, B. R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 295
PIK3CA mutation status in Japanese lung cancer patients
Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.07.006 · Cited by 273
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
Rel/NF-κB transcription factors and the control of apoptosis
Sonenshein, G. E. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0062 · Cited by 238
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228
Massion, P. P., Kuo, W.-L., Stokoe, D., Olshen, A. B., TRESELER, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., et al. (2002) · PubMed · Cited by 222
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang, S. I., Parsons, R. E., & Ittmann, M. (1998) · PubMed · Cited by 218
AKT1E17K in human solid tumours
Bleeker, F. E., Felicioni, L., Buttitta, F., Lamba, S., Cardone, L., Rodolfo, M., Scarpa, A., Leenstra, S., Frattini, M., Barbareschi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.170 · Cited by 209
O'Byrne, K. J., Gatzemeier, U., Bondarenko, I., Barrios, C., Eschbach, C., Martens, U. M., Hotko, Y., Kortsik, C., Paz-Ares, L., Pereira, J. R., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70189-9 · Cited by 205
Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., de Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5485 · Cited by 190
Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K., Kim, H., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184
Spoerke, J. M., O'Brien, C., Huw, L., Koeppen, H., Fridlyand, J., Brachmann, R. K., Haverty, P. M., Pandita, A., Mohan, S., Sampath, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2347 · Cited by 182
Activity of any class IA PI3K isoform can sustain cell proliferation and survival
Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., & Vanhaesebroeck, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906461107 · Cited by 166
Soria, J.-C., Shepherd, F. A., Douillard, J.-Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp060 · Cited by 163
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 162
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 158
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S., Swales, K. E., Decordova, S., DeYoung, M. P., Smith, D. A., Sundaram, S. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0725 · Cited by 149
Scheffler, M., Bos, M., Gardizi, M., König, K., Michels, S., Fassunke, J., Heydt, C., Künstlinger, H., Ihle, M., Ueckeroth, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2834 · Cited by 147
PIK3CA mutation and amplification in human lung cancer
Okudela, K., Suzuki, M., Kageyama, S., Bunai, T., Nagura, K., Igarashi, H., Takamochi, K., Suzuki, K. Z., Yamada, T., Niwa, H., et al. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02155.x · Cited by 142
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Miller, C. T., Moy, J. R., Lin, L., Schipper, M. J., Normolle, D. P., Brenner, D. E., Iannettoni, M. D., Orringer, M. B., & Beer, D. G. (2003) · PubMed · Cited by 135
Utermark, T., Rao, T., Cheng, H.-L. M., Wang, Q., Lee, S., Wang, Z. C., Iglehart, J. D., Roberts, T. M., Muller, W. J., & Zhao, J. J. (2012) · Genes & Development · doi:10.1101/gad.191973.112 · Cited by 132
Molecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K Signaling
Conde, E., Angulo, B., Tang, M., Morente, M. M., Torres‐Lanzas, J., Encuentra, Á. L., López‐Ríos, F., & Sánchez‐Céspedes, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1362 · Cited by 118
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Price, K. A. R., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W. J., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec1531 · Cited by 97
PIK3CA mutations in glioblastoma multiforme
Hartmann, C. J., Bartels, G., Gehlhaar, C., Holtkamp, N., & von Deimling, A. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1000-1 · Cited by 95
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)
Ji, M., Guan, H., Gao, C., Shi, B., & Hou, P. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-147 · Cited by 91
Chen, X., Chang, C., Spoerke, J. M., Yoh, K. E., Kapoor, V., Baudo, C. D., Aimi, J., Yu, M., Liang-Chu, M. M. Y., Suttmann, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1593 · Cited by 91
Identification of PTEN mutations in metastatic melanoma specimens
Çelebi, J. T., Shendrik, I., Silvers, D. N., & Peacocke, M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.653 · Cited by 90
Langer, C. J., Redman, M. W., Wade, J. L., Aggarwal, C., Bradley, J. D., Crawford, J., Stella, P. J., Knapp, M. H., Miao, J., Minichiello, K., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.029 · Cited by 88
Lara, P. N., Longmate, J., Mack, P. C., Kelly, K. L., Socinski, M. A., Salgia, R., Gitlitz, B. J., Li, T., Koczywas, M., Reckamp, K. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3281 · Cited by 86
Murthy, S. S., Tosolini, A., Taguchi, T., & Testa, J. R. (2000) · Cytogenetic and Genome Research · doi:10.1159/000015481 · Cited by 78
Besse, B., Leighl, N. B., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J., Gogov, S., Miller, N., Jehl, V., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt536 · Cited by 65
Bowles, D. W., Ma, W. W., Senzer, N. N., Brahmer, J. R., Adjei, A. A., Davies, M. A., Lazar, A. J., Vo, A. C. H., Peterson, S., Walker, L. N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
Dhillon, T., Mauri, F. A., Bellezza, G., Cagini, L., Barbareschi, M., North, B. V., & Seckl, M. J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce6604 · Cited by 61
Dobashi, Y., Suzuki, S., Matsubara, H., Kimura, M., Endo, S., & Ooi, A. (2008) · Cancer · doi:10.1002/cncr.23996 · Cited by 53
Gandhi, L., Besse, B., Mazières, J., Waqar, S. N., Cortot, A. B., Barlési, F., Quoix, É., Otterson, G. A., Ettinger, D. S., Horn, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.398 · Cited by 53
Hiramatsu, M., Ninomiya, H., Inamura, K., Nomura, K., Takeuchi, K., Satoh, Y., Okumura, S., Nakagawa, K., Yamori, T., Matsuura, M., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.001 · Cited by 52
Levy, B. P., Spira, A. I., Becker, D. J., Evans, T. L., Schnadig, I. D., Camidge, D. R., Bauman, J. E., Hausman, D. F., Walker, L. N., Nemunaitis, J. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000183 · Cited by 52
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 50
Dobashi, Y., Suzuki, S., Kimura, M., Matsubara, H., Tsubochi, H., Imoto, I., & Ooi, A. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.025 · Cited by 49
Luk, S. K., Piekorz, R. P., Nürnberg, B., & To, S. S. T. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.006 · Cited by 48
Gately, K. A., Al-Alao, B. S., Dhillon, T., Mauri, F. A., Cuffe, S. D., Seckl, M. J., & O'Byrne, K. J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.012 · Cited by 44
The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Herrera, V. A., Zeindl‐Eberhart, E., Jung, A., Huber, R. M., & Bergner, A. (2011) · PubMed · Cited by 43
Soria, J., Adjei, A. A., Bahleda, R., Besse, B., Ferté, C., Planchard, D., Zhou, J., Ware, J. A., Morrissey, K. M., Shankar, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.027 · Cited by 42
Molecular Dissection of AKT Activation in Lung Cancer Cell Lines
Guo, Y., Du, J., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0558 · Cited by 41
Riely, G. J., Brahmer, J. R., Planchard, D., Crinò, L., Doebele, R. C., Lopez, L. A. M., Gettinger, S. N., Schumann, C., Li, X. N., Atkins, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7531 · Cited by 39
Bedard, P. L., Davies, M. A., Kopetz, S., Juric, D., Shapiro, G. I., Luke, J. J., Spreafico, A., Wu, B., Castell, C., Gomez, C., et al. (2017) · Cancer · doi:10.1002/cncr.31044 · Cited by 37
Vansteenkiste, J., Solomon, B., Boyer, M. J., Wolf, J., Miller, N., Scala, L. D., Pylvaenaeinen, I., Petrovic, K., Dimitrijević, S., Anrys, B., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307ede · Cited by 33
Yamamoto, N., Fujiwara, Y., Tamura, K., Kondo, S., Iwasa, S., Tanabe, Y., Horiike, A., Yanagitani, N., Kitazono, S., Inatani, M., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0382-3 · Cited by 32
Tan, D. S.-W., Lim, K. H., Tai, W. M. D., Ahmad, A., Pan, S., Ng, Q. S., Ang, M., Gogna, A., Ng, Y. L., Tan, B. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8107 · Cited by 30
Morán, T., Palmero, R., Provencio, M., Insa, A., Majem, M., Reguart, N., Bosch‐Barrera, J., Isla, D., Carcereny, E., Lee, C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.009 · Cited by 26
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy
Dobashi, Y. (2010) · Frontiers in bioscience · doi:10.2741/3815 · Cited by 13
Wainberg, Z. A., Shapiro, G. I., Curigliano, G., Kristeleit, R. S., Leong, S., Alsina, M., Milella, M., Britten, C. D., Gelmon, K. A., Olszanski, A. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2566 · Cited by 9
Cited by
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Heidarnejad maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 328
Metadata
- Authors
- Tan, A. C.
- Venue
- Thoracic Cancer
- Publisher
- Wiley
- Published
- 2020-01-27
- Volume
- 11
- Issue
- 3
- Pages
- 511-518
- ISSN
- 1759-7706 (ISSN-L)
- 1759-7714
- OpenAlex
- W3003807413
- Cited by
- 528
- References
- 82
- FWCI
- 19.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.